demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 all comersCOVID-19 severe or critically
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 severe or critically
sarilumab CORIMUNO-SARI-1 ... sarilumab Sanofi phase 3 US ARI-RAF ... sarilumab Sanofi phase 3 outside US REMAP-CAP sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose Lescure ...
sarilumab low dose (200mg) sarimulab phase 2 low dose Lescure ...

0 studies excluded by filtering options 2